Functional Constipation (FC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Functional Constipation (FC) Market Outlook

Thelansis’s “Functional Constipation (FC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Functional Constipation (FC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Functional Constipation (FC) Overview

Functional constipation (FC) is a condition that is diagnosed according to the Rome IV criteria. It involves the presence of two or more of the following symptoms: straining during at least 25% of defecations, lumpy or hard stools in at least 25% of defecations, the sensation of incomplete evacuation for at least 25% of defecations, the sensation of anorectal obstruction/blockage for at least 25% of defecations, manual manoeuvres to facilitate at least 25% of defecations, and fewer than three spontaneous bowel movements per week. Loose stools are rarely present in functional constipation without using laxatives, and the patient should not meet the criteria for irritable bowel syndrome. Functional constipation (FC) has three subtypes: normal transit constipation, slow transit constipation, and outlet constipation. Normal transit constipation occurs when there is a self-reported perception of constipation despite normal stool movement through the colon. Slow transit constipation occurs when there is prolonged transit time through the colon, as confirmed by a motility study. Outlet constipation (dyssynergic defecation) results from pelvic floor dysfunction when there is a defect in the coordination required for stool evacuation. Treatment for functional constipation depends on the underlying cause. Slow transit constipation can benefit from increased fluid intake, fibre supplementation, magnesium supplementation, and stool softener or laxative use. Non-stimulant laxatives are preferred to stimulant laxatives because the latter can cause dependency and decreased bowel function over time. Pelvic floor PT is recommended for treating dyssynergic defecation.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Functional Constipation (FC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034